Similarly, hypoxia increases gefitinib-resistant lung CSCs in EGFR mutation-positive NSCLC by upregulating expression of insulin-like growth factor 1 (IGF1) through HIF1α and activating IGF1 receptor (IGF1R) [118]. This evidence concerns the gene IGF1 and non-small cell lung carcinoma.